Trial Profile

A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients With EGFR Mutant Non-Small Cell Lung Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BLU-945 (Primary) ; Osimertinib (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
Acronyms SYMPHONY
Sponsors Blueprint Medicines

Most Recent Events

15 Mar 2024 Status changed from active, no longer recruiting to discontinued.
08 Feb 2024 This trial has been Discontinued in Spain, According to European Clinical Trials Database record.
03 Feb 2024 This trial has been Discontinued in Germany, According to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com